摘要
背景:淀粉样β(Aβ)诱导的线粒体功能障碍是阿尔茨海默病神经元毒性的主要原因之一。最近的一些报告表明,线粒体的改变通过细胞内聚集的低聚Aβ。这些改变包括增加线粒体活性氧(ROS),线粒体DNA的损耗,降低氧化磷酸化和ATP的产生,细胞膜去极化,降低线粒体等所有这些缺陷累积导致细胞能量平衡的神经毒变异数。另一方面,消炎药报告促进线粒体生物合成和改善细胞能量状 方法:综合上述线索,我们评价阿司匹林对β42诱导的毒性和线粒体分化的保护作用。 结果:aβ42处理的细胞明显减少,细胞凋亡增加,MTT法、细胞凋亡ELISA和神经元细胞β-微管蛋白抗体免疫荧光染色明显。在Mitotracker Red FM染色和线粒体DNA的强度观察nDNA比也随之减少,提示线粒体膜去极化和/或减少线粒体数目随着线粒体DNA缺失。然而,同时处理5μm的阿司匹林对低聚Aβ42处理的细胞保护他们免受线粒体功能障碍和神经毒性。 结论:我们建议线粒体生物合成、线粒体膜电位的改变和(或)阿司匹林对β42聚集的抑制作用作为可能的机制
关键词: 阿司匹林,oligomeric-aβ42,EC P19细胞,线粒体功能障碍,神经毒性,线粒体DNA和RNA
Current Alzheimer Research
Title:Protective Effect of Aspirin Against Oligomeric Aβ42 Induced Mitochondrial Alterations and Neurotoxicity in Differentiated EC P19 Neuronal Cells
Volume: 14 Issue: 8
关键词: 阿司匹林,oligomeric-aβ42,EC P19细胞,线粒体功能障碍,神经毒性,线粒体DNA和RNA
摘要: Background: Amyloid-beta (Aβ) induced mitochondrial dysfunction is one of the major causes of neuronal toxicity in Alzheimer’s disease. A number of recent reports suggest involvement of mitochondrial alterations through intracellular accumulation of oligomeric Aβ. These mitochondrial alterations include increased Reactive Oxygen Species (ROS), mt-DNA depletion, decreased oxidative phosphorylation and ATP production, membrane depolarization, reduced number of mitochondria etc. All these defects cumulatively caused neural toxicity and alterations in cellular energy homeostasis. On the other hand, anti-inflammatory drug aspirin is reported to promote both mitochondrial biogenesis and improvement in cellular energy status.
Methods: Taking altogether the mentioned clues, we evaluated protective effect of aspirin, if any on oligomeric Aβ42 induced toxicity and mitochondrial alterations in differentiated neuronal cells. Results: A significant reduction in neuronal viability and increased apoptosis was observed in Aβ42 treated cells, as evident by MTT assay, apoptosis ELISA and immunofluorescence from β-III tubulin antibody staining of neuronal cells. A concomitant decrease was also observed in the intensity of mitotracker red FM staining and mt-DNA to nDNA ratio, suggesting mitochondrial membrane depolarization and/or reduced number of mitochondria along with depletion in mt-DNA. However, simultaneous treatment of 5 μM aspirin to oligomeric Aβ42 treated cells protected them from mitochondrial dysfunction and neurotoxicity. Conclusion: We suggest mitochondrial biogenesis, changes in mitochondrial membrane potential and / or inhibition of Aβ42 aggregation by aspirin as possible underlying mechanism(s).Export Options
About this article
Cite this article as:
Protective Effect of Aspirin Against Oligomeric Aβ42 Induced Mitochondrial Alterations and Neurotoxicity in Differentiated EC P19 Neuronal Cells, Current Alzheimer Research 2017; 14 (8) . https://dx.doi.org/10.2174/1567205014666170203104757
DOI https://dx.doi.org/10.2174/1567205014666170203104757 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers
Anti-Cancer Agents in Medicinal Chemistry Regional Differences in Adaptation of CNS Mu Opioid Receptors to Chronic Opioid Agonist Administration
Current Neuropharmacology Rifampicin Induced Aggregation of Ovalbumin: Malicious Behaviour of Antibiotics
Protein & Peptide Letters Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Peptides for Tumour Therapy and Diagnosis: Current Status and Future Directions
Current Medicinal Chemistry Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer’s Disease: A Systematic Review
Current Neuropharmacology Nanofibre Based Smart Pharmaceutical Scaffolds for Wound Repair and Regenerations
Current Pharmaceutical Design Recent Advances in Nanotechnology-Based Drug Delivery Approaches for Alzheimer disease
Current Drug Targets Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets QSAR Approaches Applied to Antidepressants Induced Neurogenesis - in vivo and in silico Applications
Mini-Reviews in Medicinal Chemistry Targeting Cancer Stem Cells: Promises and Challenges
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
Endocrine, Metabolic & Immune Disorders - Drug Targets TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Long Non-Coding RNAs in Nervous System Cancers: New Insights in Prognosis, Diagnosis and Therapy
Current Medicinal Chemistry Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets Cyclization in Opioid Peptides
Current Drug Targets